ID   TNR6_HUMAN              Reviewed;         335 AA.
AC   P25445; A9UJX4; B6VNV4; Q14292; Q14293; Q14294; Q14295; Q16652; Q5T9P1;
AC   Q5T9P2; Q5T9P3; Q6SSE9;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   18-JUN-2025, entry version 274.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 6;
DE   AltName: Full=Apo-1 antigen;
DE   AltName: Full=Apoptosis-mediating surface antigen FAS;
DE   AltName: Full=FASLG receptor;
DE   AltName: CD_antigen=CD95;
DE   Flags: Precursor;
GN   Name=FAS; Synonyms=APT1, FAS1, TNFRSF6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RX   PubMed=1713127; DOI=10.1016/0092-8674(91)90614-5;
RA   Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M.,
RA   Hase A., Seto Y., Nagata S.;
RT   "The polypeptide encoded by the cDNA for human cell surface antigen Fas can
RT   mediate apoptosis.";
RL   Cell 66:233-243(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 226-240;
RP   269-291 AND 321-335.
RX   PubMed=1375228; DOI=10.1016/s0021-9258(19)50076-x;
RA   Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M.,
RA   Richards S., Dhein J., Trauth B.C., Ponstingl H., Krammer P.H.;
RT   "Purification and molecular cloning of the APO-1 cell surface antigen, a
RT   member of the tumor necrosis factor/nerve growth factor receptor
RT   superfamily. Sequence identity with the Fas antigen.";
RL   J. Biol. Chem. 267:10709-10715(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 6), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7575433; DOI=10.1042/bj3100957;
RA   Liu C., Cheng J., Mountz J.D.;
RT   "Differential expression of human Fas mRNA species upon peripheral blood
RT   mononuclear cell activation.";
RL   Biochem. J. 310:957-963(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 6), AND FUNCTION.
RX   PubMed=7533181;
RA   Cascino I., Fiucci G., Papoff G., Ruberti G.;
RT   "Three functional soluble forms of the human apoptosis-inducing Fas
RT   molecule are produced by alternative splicing.";
RL   J. Immunol. 154:2706-2713(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RX   PubMed=8598453;
RA   Cascino I., Papoff G., De Maria R., Testi R., Ruberti G.;
RT   "Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain
RT   protects tumor cells from Fas-mediated apoptosis.";
RL   J. Immunol. 156:13-17(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5).
RX   PubMed=8648105;
RA   Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberti G.;
RT   "An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents
RT   cell death in vitro.";
RL   J. Immunol. 156:4622-4630(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALPS1A SER-262.
RX   PubMed=17336828; DOI=10.1016/j.imbio.2006.12.003;
RA   Del-Rey M.J., Manzanares J., Bosque A., Aguilo J.I., Gomez-Rial J.,
RA   Roldan E., Serrano A., Anel A., Paz-Artal E., Allende L.M.;
RT   "Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new
RT   germline Fas gene mutation.";
RL   Immunobiology 212:73-83(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Peripheral blood lymphocyte;
RA   Schaetzlein C.E., Poehlmann R., Philippsen P., Eibel H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   De La Calle-Martin O.;
RL   Submitted (OCT-2008) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-16; ILE-122 AND
RP   ILE-305.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   INTERACTION WITH RIPK1.
RX   PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [16]
RP   FUNCTION, AND IDENTIFICATION IN DISC COMPLEX.
RX   PubMed=9184224; DOI=10.1093/emboj/16.10.2794;
RA   Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M.,
RA   Krammer P.H., Peter M.E.;
RT   "FLICE is activated by association with the CD95 death-inducing signaling
RT   complex (DISC).";
RL   EMBO J. 16:2794-2804(1997).
RN   [17]
RP   INTERACTION WITH FEM1B.
RX   PubMed=10542291; DOI=10.1074/jbc.274.45.32461;
RA   Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y., Yu V.C.;
RT   "F1Aalpha, a death receptor-binding protein homologous to the
RT   Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase
RT   substrate that mediates apoptosis.";
RL   J. Biol. Chem. 274:32461-32468(1999).
RN   [18]
RP   INTERACTION WITH FAIM2.
RX   PubMed=10535980; DOI=10.1073/pnas.96.22.12667;
RA   Somia N.V., Schmitt M.J., Vetter D.E., Van Antwerp D., Heinemann S.F.,
RA   Verma I.M.;
RT   "LFG: an anti-apoptotic gene that provides protection from fas-mediated
RT   cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12667-12672(1999).
RN   [19]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [20]
RP   INTERACTION WITH BABAM2.
RX   PubMed=15465831; DOI=10.1074/jbc.m408678200;
RA   Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L., Ho T.C.-Y.,
RA   Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H., Chan J.Y.-H., Chui Y.-L.;
RT   "A death receptor-associated anti-apoptotic protein, BRE, inhibits
RT   mitochondrial apoptotic pathway.";
RL   J. Biol. Chem. 279:52106-52116(2004).
RN   [21]
RP   INTERACTION WITH DDX3X; GSK3B AND BIRC2.
RX   PubMed=18846110; DOI=10.1038/cdd.2008.124;
RA   Sun M., Song L., Li Y., Zhou T., Jope R.S.;
RT   "Identification of an antiapoptotic protein complex at death receptors.";
RL   Cell Death Differ. 15:1887-1900(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-209, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-118.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [25]
RP   INTERACTION WITH FADD.
RX   PubMed=21109225; DOI=10.1016/j.ajhg.2010.10.028;
RA   Bolze A., Byun M., McDonald D., Morgan N.V., Abhyankar A., Premkumar L.,
RA   Puel A., Bacon C.M., Rieux-Laucat F., Pang K., Britland A., Abel L.,
RA   Cant A., Maher E.R., Riedl S.J., Hambleton S., Casanova J.L.;
RT   "Whole-exome-sequencing-based discovery of human FADD deficiency.";
RL   Am. J. Hum. Genet. 87:873-881(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   GLYCOSYLATION AT THR-28, STRUCTURE OF CARBOHYDRATES, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.m111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of N- and
RT   O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 11:1-17(2012).
RN   [29]
RP   GLYCOSYLATION AT ARG-250 (MICROBIAL INFECTION).
RX   PubMed=23955153; DOI=10.1038/nature12436;
RA   Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L.,
RA   Chen X., Chen S., Shao F.;
RT   "Pathogen blocks host death receptor signalling by arginine GlcNAcylation
RT   of death domains.";
RL   Nature 501:242-246(2013).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-199, AND MUTAGENESIS OF
RP   CYS-199.
RX   PubMed=25301068; DOI=10.1038/cdd.2014.153;
RA   Rossin A., Durivault J., Chakhtoura-Feghali T., Lounnas N.,
RA   Gagnoux-Palacios L., Hueber A.O.;
RT   "Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas
RT   stability.";
RL   Cell Death Differ. 22:643-653(2015).
RN   [32]
RP   GLYCOSYLATION AT ARG-250 (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-250.
RX   PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028;
RA   Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.;
RT   "Structural and functional insights into host death domains inactivation by
RT   the bacterial arginine GlcNAcyltransferase effector.";
RL   Mol. Cell 74:922-935(2019).
RN   [33]
RP   STRUCTURE BY NMR OF 218-335.
RX   PubMed=8967952; DOI=10.1038/384638a0;
RA   Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W.;
RT   "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.";
RL   Nature 384:638-641(1996).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 223-335 IN COMPLEX WITH FADD,
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-291 AND
RP   ILE-313.
RX   PubMed=19118384; DOI=10.1038/nature07606;
RA   Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E.,
RA   Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J.;
RT   "The Fas-FADD death domain complex structure unravels signalling by
RT   receptor clustering.";
RL   Nature 457:1019-1022(2009).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 230-254 IN COMPLEX WITH CALM, AND
RP   CALMODULIN-BINDING.
RX   PubMed=24914971; DOI=10.1107/s1399004714006919;
RA   Jiang T., Cao P., Gong Y., Yu H.J., Gui W.J., Zhang W.T.;
RT   "Structural insights into the mechanism of calmodulin binding to death
RT   receptors.";
RL   Acta Crystallogr. D 70:1604-1613(2014).
RN   [36]
RP   VARIANT ALPS1A PRO-241.
RX   PubMed=7540117; DOI=10.1016/0092-8674(95)90013-6;
RA   Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A.,
RA   Lin A.Y., Strober W., Lenardo M.J., Puck J.M.;
RT   "Dominant interfering Fas gene mutations impair apoptosis in a human
RT   autoimmune lymphoproliferative syndrome.";
RL   Cell 81:935-946(1995).
RN   [37]
RP   VARIANT ALPS1A TYR-260.
RX   PubMed=8929361; DOI=10.1056/nejm199611283352204;
RA   Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B.;
RT   "Fas gene mutations in the Canale-Smith syndrome, an inherited
RT   lymphoproliferative disorder associated with autoimmunity.";
RL   N. Engl. J. Med. 335:1643-1649(1996).
RN   [38]
RP   VARIANTS ALPS1A TRP-121 AND CYS-232.
RX   PubMed=9028321;
RA   Bettinardi A., Brugnoni D., Quiros-Roldan E., Malagoli A., La Grutta S.,
RA   Correra A., Notarangelo L.D.;
RT   "Missense mutations in the Fas gene resulting in autoimmune
RT   lymphoproliferative syndrome: a molecular and immunological analysis.";
RL   Blood 89:902-909(1997).
RN   [39]
RP   VARIANTS ALPS1A ASP-257 AND SER-310.
RX   PubMed=9028957;
RA   Sneller M.C., Wang J., Dale J.K., Strober W., Middelton L.A., Choi Y.,
RA   Fleisher T.A., Lim M.S., Jaffe E.S., Puck J.M., Lenardo M.J., Straus S.E.;
RT   "Clinical, immunologic, and genetic features of an autoimmune
RT   lymphoproliferative syndrome associated with abnormal lymphocyte
RT   apoptosis.";
RL   Blood 89:1341-1348(1997).
RN   [40]
RP   VARIANT ALPS1A ALA-28.
RX   PubMed=9322534; DOI=10.1053/gast.1997.v113.pm9322534;
RA   Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R., Natoli G.,
RA   Nisini R., Almerighi C., Balsano C., Vajro P., Vegnente A., Levrero M.;
RT   "Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a
RT   patient with type 2 autoimmune hepatitis.";
RL   Gastroenterology 113:1384-1389(1997).
RN   [41]
RP   VARIANTS NON-HODGKIN LYMPHOMA THR-25; PHE-180; LEU-183; ILE-198; VAL-260;
RP   LYS-264; LYS-272; PHE-278 AND ASN-299.
RX   PubMed=9787134;
RA   Groenbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K.,
RA   Hansen N.E., Zeuthen J., Hou-Jensen K., Guldberg P.;
RT   "Somatic Fas mutations in non-Hodgkin's lymphoma: association with
RT   extranodal disease and autoimmunity.";
RL   Blood 92:3018-3024(1998).
RN   [42]
RP   VARIANT ALPS1A VAL-260.
RX   PubMed=9821419; DOI=10.1016/s0022-3476(98)70102-7;
RA   Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J.,
RA   Jackson C.E., Wang J., Fleisher T., Straus S.E., Puck J.M.;
RT   "The clinical spectrum in a large kindred with autoimmune
RT   lymphoproliferative syndrome caused by a Fas mutation that impairs
RT   lymphocyte apoptosis.";
RL   J. Pediatr. 133:629-633(1998).
RN   [43]
RP   VARIANTS ALPS1A LYS-241 AND GLN-250.
RX   PubMed=10090885; DOI=10.1086/302333;
RA   Jackson C.E., Fischer R.E., Hsu A.P., Anderson S.M., Choi Y., Wang J.,
RA   Dale J.K., Fleisher T.A., Middelton L.A., Sneller M.C., Lenardo M.J.,
RA   Straus S.E., Puck J.M.;
RT   "Autoimmune lymphoproliferative syndrome with defective Fas: genotype
RT   influences penetrance.";
RL   Am. J. Hum. Genet. 64:1002-1014(1999).
RN   [44]
RP   VARIANTS ALPS1A LEU-249; PRO-250; ASP-253; SER-253; ARG-259; LYS-270 AND
RP   LYS-272.
RX   PubMed=10515860;
RA   Rieux-Laucat F., Blachere S., Danielan S., De Villartay J.P., Oleastro M.,
RA   Solary E., Bader-Meunier B., Arkwright P., Pondare C., Bernaudin F.,
RA   Chapel H., Nielsen S., Berrah M., Fischer A., Le Deist F.;
RT   "Lymphoproliferative syndrome with autoimmunity: A possible genetic basis
RT   for dominant expression of the clinical manifestations.";
RL   Blood 94:2575-2582(1999).
RN   [45]
RP   VARIANT ALPS1A GLY-272.
RX   PubMed=10340403; DOI=10.1016/s0301-472x(99)00033-8;
RA   Peters A.M., Kohfink B., Martin H., Griesinger F., Wormann B., Gahr M.,
RA   Roesler J.;
RT   "Defective apoptosis due to a point mutation in the death domain of CD95
RT   associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma,
RT   and Hodgkin's disease.";
RL   Exp. Hematol. 27:868-874(1999).
RN   [46]
RP   VARIANTS ALPS1A ARG-82; PRO-250; GLY-260 AND ILE-270.
RX   PubMed=9927496; DOI=10.1172/jci5121;
RA   Vaishnaw A.K., Orlinick J.R., Chu J.-L., Krammer P.H., Chao M.V.,
RA   Elkon K.B.;
RT   "The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-
RT   1) mutations.";
RL   J. Clin. Invest. 103:355-363(1999).
RN   [47]
RP   VARIANTS SQUAMOUS CELL CARCINOMA SER-118; ARG-178 AND ASP-255.
RX   PubMed=10620127; DOI=10.1046/j.1523-1747.2000.00819.x;
RA   Lee S.H., Shin M.S., Kim H.S., Park W.S., Kim S.Y., Jang J.J., Rhim K.J.,
RA   Jang J., Lee H.K., Park J.Y., Oh R.R., Han S.Y., Lee J.H., Lee J.Y.,
RA   Yoo N.J.;
RT   "Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell
RT   carcinoma arising from a burn scar.";
RL   J. Invest. Dermatol. 114:122-126(2000).
RN   [48]
RP   VARIANTS ALPS1A PRO-241; VAL-260; ILE-270 AND GLY-272.
RX   PubMed=11418480; DOI=10.1182/blood.v98.1.194;
RA   Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Roesen-Wolff A.,
RA   Peters A.M.J., Sneller M.C., Hallahan C.W., Wang J., Fischer R.E.,
RA   Jackson C.M., Lin A.Y., Baeumler C., Siegert E., Marx A., Vaishnaw A.K.,
RA   Grodzicky T., Fleisher T.A., Lenardo M.J.;
RT   "The development of lymphomas in families with autoimmune
RT   lymphoproliferative syndrome with germline Fas mutations and defective
RT   lymphocyte apoptosis.";
RL   Blood 98:194-200(2001).
RN   [49]
RP   CHARACTERIZATION OF VARIANTS ALPS1A CYS-232; GLN-250; ASP-257; TYR-260;
RP   VAL-260; LYS-270 AND LYS-272, AND MUTAGENESIS OF ARG-250; GLU-261; GLN-283
RP   AND LYS-287.
RX   PubMed=20935634; DOI=10.1038/nsmb.1920;
RA   Wang L., Yang J.K., Kabaleeswaran V., Rice A.J., Cruz A.C., Park A.Y.,
RA   Yin Q., Damko E., Jang S.B., Raunser S., Robinson C.V., Siegel R.M.,
RA   Walz T., Wu H.;
RT   "The Fas-FADD death domain complex structure reveals the basis of DISC
RT   assembly and disease mutations.";
RL   Nat. Struct. Mol. Biol. 17:1324-1329(2010).
CC   -!- FUNCTION: Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits
CC       caspase CASP8 to the activated receptor. The resulting death-inducing
CC       signaling complex (DISC) performs CASP8 proteolytic activation which
CC       initiates the subsequent cascade of caspases (aspartate-specific
CC       cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may
CC       have a role in the induction of peripheral tolerance, in the antigen-
CC       stimulated suicide of mature T-cells, or both. The secreted isoforms 2
CC       to 6 block apoptosis (in vitro). {ECO:0000269|PubMed:19118384,
CC       ECO:0000269|PubMed:7533181, ECO:0000269|PubMed:9184224}.
CC   -!- SUBUNIT: Component of the death-induced signaling complex (DISC)
CC       composed of cell surface receptor FAS/CD95, adapter protein FADD and
CC       the CASP8 protease; recruitment of CASP8 to the complex is required for
CC       processing of CASP8 into the p18 and p10 subunits (PubMed:21109225,
CC       PubMed:9184224, PubMed:9322534). Interacts directly (via DED domain)
CC       with NOL3 (via CARD domain); inhibits death-inducing signaling complex
CC       (DISC) assembly by inhibiting the increase in FAS-FADD binding induced
CC       by FAS activation (By similarity). Binds DAXX. Interacts with HIPK3 (By
CC       similarity). Part of a complex containing HIPK3 and FADD (By
CC       similarity). Binds RIPK1 and FAIM2 (PubMed:10535980, PubMed:7538908).
CC       Interacts with BABAM2 and FEM1B (PubMed:10542291, PubMed:15465831).
CC       Interacts with CALM (PubMed:24914971). In the absence of stimulation,
CC       interacts with BIRC2, DDX3X and GSK3B. The interaction with BIRC2 and
CC       DDX3X is further enhanced upon receptor stimulation and accompanied by
CC       DDX3X and BIRC2 cleavage (PubMed:18846110).
CC       {ECO:0000250|UniProtKB:P25446, ECO:0000250|UniProtKB:Q63199,
CC       ECO:0000269|PubMed:10535980, ECO:0000269|PubMed:10542291,
CC       ECO:0000269|PubMed:15465831, ECO:0000269|PubMed:18846110,
CC       ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:21109225,
CC       ECO:0000269|PubMed:24914971, ECO:0000269|PubMed:7538908,
CC       ECO:0000269|PubMed:9184224, ECO:0000269|PubMed:9322534}.
CC   -!- INTERACTION:
CC       P25445; P62158: CALM3; NbExp=4; IntAct=EBI-494743, EBI-397435;
CC       P25445; Q14790: CASP8; NbExp=15; IntAct=EBI-494743, EBI-78060;
CC       P25445; Q03135: CAV1; NbExp=3; IntAct=EBI-494743, EBI-603614;
CC       P25445; Q9UER7: DAXX; NbExp=3; IntAct=EBI-494743, EBI-77321;
CC       P25445; Q13158: FADD; NbExp=22; IntAct=EBI-494743, EBI-494804;
CC       P25445; P25445: FAS; NbExp=3; IntAct=EBI-494743, EBI-494743;
CC       P25445; P48023: FASLG; NbExp=4; IntAct=EBI-494743, EBI-495538;
CC       P25445; P29590: PML; NbExp=4; IntAct=EBI-494743, EBI-295890;
CC       P25445; Q15156: PML-RAR; NbExp=6; IntAct=EBI-494743, EBI-867256;
CC       P25445; Q12923: PTPN13; NbExp=3; IntAct=EBI-494743, EBI-355227;
CC       P25445; P12931: SRC; NbExp=2; IntAct=EBI-494743, EBI-621482;
CC       P25445; P12815: Pdcd6; Xeno; NbExp=2; IntAct=EBI-494743, EBI-309164;
CC       P25445-1; Q14790: CASP8; NbExp=3; IntAct=EBI-15749113, EBI-78060;
CC       P25445-1; Q03135: CAV1; NbExp=3; IntAct=EBI-15749113, EBI-603614;
CC       P25445-1; Q13158: FADD; NbExp=17; IntAct=EBI-15749113, EBI-494804;
CC       P25445-1; P07947: YES1; NbExp=2; IntAct=EBI-15749113, EBI-515331;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:1713127, ECO:0000269|PubMed:25301068}; Single-pass
CC       type I membrane protein {ECO:0000305}. Membrane raft
CC       {ECO:0000269|PubMed:25301068}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 5]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 6]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P25445-1; Sequence=Displayed;
CC       Name=2; Synonyms=del2, D;
CC         IsoId=P25445-2; Sequence=VSP_006481, VSP_006482;
CC       Name=3; Synonyms=del3, E;
CC         IsoId=P25445-3; Sequence=VSP_006483, VSP_006484;
CC       Name=4; Synonyms=B;
CC         IsoId=P25445-4; Sequence=VSP_006485, VSP_006486;
CC       Name=5; Synonyms=C;
CC         IsoId=P25445-5; Sequence=VSP_006487, VSP_006488;
CC       Name=6; Synonyms=TMdel, A;
CC         IsoId=P25445-6; Sequence=VSP_006489;
CC       Name=7; Synonyms=FasExo8Del;
CC         IsoId=P25445-7; Sequence=VSP_045235, VSP_045236;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 6 are expressed at equal
CC       levels in resting peripheral blood mononuclear cells. After activation
CC       there is an increase in isoform 1 and decrease in the levels of isoform
CC       6. {ECO:0000269|PubMed:7575433}.
CC   -!- DOMAIN: Contains a death domain involved in the binding of FADD, and
CC       maybe to other cytosolic adapter proteins.
CC   -!- PTM: (Microbial infection) Glycosylated at Arg-250 by enteropathogenic
CC       E.coli protein NleB1: arginine GlcNAcylation prevents
CC       homotypic/heterotypic death domain interactions.
CC       {ECO:0000305|PubMed:23955153}.
CC   -!- PTM: Palmitoylated (PubMed:25301068). Palmitoylation by ZDHHC7 prevents
CC       the lysosomal degradation of FAS regulating its expression at the
CC       plasma membrane (PubMed:25301068). {ECO:0000269|PubMed:25301068}.
CC   -!- PTM: N- and O-glycosylated. O-glycosylated with core 1 or possibly core
CC       8 glycans. {ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Autoimmune lymphoproliferative syndrome 1A (ALPS1A)
CC       [MIM:601859]: A disorder of apoptosis that manifests in early childhood
CC       and results in the accumulation of autoreactive lymphocytes. It is
CC       characterized by non-malignant lymphadenopathy with hepatosplenomegaly,
CC       and autoimmune hemolytic anemia, thrombocytopenia and neutropenia.
CC       {ECO:0000269|PubMed:10090885, ECO:0000269|PubMed:10340403,
CC       ECO:0000269|PubMed:10515860, ECO:0000269|PubMed:11418480,
CC       ECO:0000269|PubMed:17336828, ECO:0000269|PubMed:20935634,
CC       ECO:0000269|PubMed:7540117, ECO:0000269|PubMed:8929361,
CC       ECO:0000269|PubMed:9028321, ECO:0000269|PubMed:9028957,
CC       ECO:0000269|PubMed:9322534, ECO:0000269|PubMed:9821419,
CC       ECO:0000269|PubMed:9927496}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Dominant negative isoform, resistant to
CC       Fas-mediated apoptosis. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome Database
CC       (ALPSbase); Note=Mutations in TNFRSF6 causing ALPS type Ia;
CC       URL="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M67454; AAA63174.1; -; mRNA.
DR   EMBL; X63717; CAA45250.1; -; mRNA.
DR   EMBL; X83490; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83491; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83492; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83493; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z47993; CAA88031.1; -; mRNA.
DR   EMBL; Z47994; CAA88032.1; -; mRNA.
DR   EMBL; Z47995; CAA88033.1; -; mRNA.
DR   EMBL; Z66556; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z70519; CAA94430.1; -; mRNA.
DR   EMBL; Z70520; CAA94431.1; -; mRNA.
DR   EMBL; AY495076; AAS76663.1; -; mRNA.
DR   EMBL; X89101; CAA61473.1; -; mRNA.
DR   EMBL; FM246458; CAR92543.1; -; mRNA.
DR   EMBL; AK290978; BAF83667.1; -; mRNA.
DR   EMBL; AY450925; AAR08906.1; -; Genomic_DNA.
DR   EMBL; AL157394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW50151.1; -; Genomic_DNA.
DR   EMBL; BC012479; AAH12479.1; -; mRNA.
DR   CCDS; CCDS7393.1; -. [P25445-1]
DR   CCDS; CCDS7394.1; -. [P25445-6]
DR   CCDS; CCDS7395.1; -. [P25445-7]
DR   PIR; A40036; A40036.
DR   PIR; I37383; I37383.
DR   PIR; I37384; I37384.
DR   PIR; S58662; S58662.
DR   RefSeq; NP_000034.1; NM_000043.6. [P25445-1]
DR   RefSeq; NP_001307548.1; NM_001320619.1.
DR   RefSeq; NP_690610.1; NM_152871.4. [P25445-6]
DR   RefSeq; NP_690611.1; NM_152872.4. [P25445-7]
DR   PDB; 1DDF; NMR; -; A=218-335.
DR   PDB; 2NA7; NMR; -; A/B/C=171-198.
DR   PDB; 3EWT; X-ray; 2.40 A; E=230-254.
DR   PDB; 3EZQ; X-ray; 2.73 A; A/C/E/G/I/K/M/O=223-335.
DR   PDB; 3THM; X-ray; 2.10 A; F=17-172.
DR   PDB; 3TJE; X-ray; 1.93 A; F=17-172.
DR   PDBsum; 1DDF; -.
DR   PDBsum; 2NA7; -.
DR   PDBsum; 3EWT; -.
DR   PDBsum; 3EZQ; -.
DR   PDBsum; 3THM; -.
DR   PDBsum; 3TJE; -.
DR   AlphaFoldDB; P25445; -.
DR   SMR; P25445; -.
DR   BioGRID; 106851; 360.
DR   CORUM; P25445; -.
DR   DIP; DIP-924N; -.
DR   FunCoup; P25445; 1444.
DR   IntAct; P25445; 113.
DR   MINT; P25445; -.
DR   STRING; 9606.ENSP00000498466; -.
DR   ChEMBL; CHEMBL4523207; -.
DR   GlyConnect; 773; 1 O-Linked glycan (1 site).
DR   GlyCosmos; P25445; 7 sites, 4 glycans.
DR   GlyGen; P25445; 10 sites, 27 N-linked glycans (2 sites), 5 O-linked glycans (7 sites).
DR   iPTMnet; P25445; -.
DR   PhosphoSitePlus; P25445; -.
DR   SwissPalm; P25445; -.
DR   BioMuta; FAS; -.
DR   DMDM; 119833; -.
DR   CPTAC; CPTAC-5953; -.
DR   CPTAC; CPTAC-5954; -.
DR   jPOST; P25445; -.
DR   MassIVE; P25445; -.
DR   PaxDb; 9606-ENSP00000347979; -.
DR   PeptideAtlas; P25445; -.
DR   ProteomicsDB; 54273; -. [P25445-1]
DR   ProteomicsDB; 54276; -. [P25445-4]
DR   ProteomicsDB; 54277; -. [P25445-5]
DR   ProteomicsDB; 54278; -. [P25445-6]
DR   ProteomicsDB; 64806; -.
DR   Pumba; P25445; -.
DR   TopDownProteomics; P25445-7; -. [P25445-7]
DR   ABCD; P25445; 12 sequenced antibodies.
DR   Antibodypedia; 4525; 3057 antibodies from 54 providers.
DR   CPTC; P25445; 2 antibodies.
DR   DNASU; 355; -.
DR   Ensembl; ENST00000355279.2; ENSP00000347426.2; ENSG00000026103.25. [P25445-7]
DR   Ensembl; ENST00000357339.7; ENSP00000349896.2; ENSG00000026103.25. [P25445-6]
DR   Ensembl; ENST00000479522.6; ENSP00000424113.1; ENSG00000026103.25. [P25445-3]
DR   Ensembl; ENST00000484444.6; ENSP00000420975.1; ENSG00000026103.25. [P25445-2]
DR   Ensembl; ENST00000488877.6; ENSP00000425159.1; ENSG00000026103.25. [P25445-4]
DR   Ensembl; ENST00000492756.7; ENSP00000422453.1; ENSG00000026103.25. [P25445-5]
DR   Ensembl; ENST00000494410.5; ENSP00000423755.1; ENSG00000026103.25. [P25445-4]
DR   Ensembl; ENST00000652046.1; ENSP00000498466.1; ENSG00000026103.25. [P25445-1]
DR   Ensembl; ENST00000697036.1; ENSP00000513060.1; ENSG00000026103.25. [P25445-4]
DR   GeneID; 355; -.
DR   KEGG; hsa:355; -.
DR   MANE-Select; ENST00000652046.1; ENSP00000498466.1; NM_000043.6; NP_000034.1.
DR   UCSC; uc001kfr.4; human. [P25445-1]
DR   AGR; HGNC:11920; -.
DR   CTD; 355; -.
DR   DisGeNET; 355; -.
DR   GeneCards; FAS; -.
DR   GeneReviews; FAS; -.
DR   HGNC; HGNC:11920; FAS.
DR   HPA; ENSG00000026103; Low tissue specificity.
DR   MalaCards; FAS; -.
DR   MIM; 134637; gene.
DR   MIM; 601859; phenotype.
DR   OpenTargets; ENSG00000026103; -.
DR   Orphanet; 3261; Autoimmune lymphoproliferative syndrome.
DR   Orphanet; 117; Behcet disease.
DR   Orphanet; 3437; Vogt-Koyanagi-Harada disease.
DR   VEuPathDB; HostDB:ENSG00000026103; -.
DR   eggNOG; ENOG502S0SV; Eukaryota.
DR   GeneTree; ENSGT00950000183126; -.
DR   HOGENOM; CLU_067123_1_0_1; -.
DR   InParanoid; P25445; -.
DR   OMA; RDTKCRC; -.
DR   OrthoDB; 8848202at2759; -.
DR   PAN-GO; P25445; 11 GO annotations based on evolutionary models.
DR   PhylomeDB; P25445; -.
DR   PathwayCommons; P25445; -.
DR   Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand.
DR   Reactome; R-HSA-3371378; Regulation by c-FLIP.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5218900; CASP8 activity is inhibited.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-69416; Dimerization of procaspase-8.
DR   Reactome; R-HSA-75157; FasL/ CD95L signaling.
DR   SignaLink; P25445; -.
DR   SIGNOR; P25445; -.
DR   BioGRID-ORCS; 355; 9 hits in 1151 CRISPR screens.
DR   ChiTaRS; FAS; human.
DR   EvolutionaryTrace; P25445; -.
DR   GeneWiki; Fas_receptor; -.
DR   GenomeRNAi; 355; -.
DR   Pharos; P25445; Tbio.
DR   PRO; PR:P25445; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P25445; protein.
DR   Bgee; ENSG00000026103; Expressed in rectum and 191 other cell types or tissues.
DR   ExpressionAtlas; P25445; baseline and differential.
DR   GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:BHF-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0005031; F:tumor necrosis factor receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IDA:MGI.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:CAFA.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IMP:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0036337; P:Fas signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; IEA:InterPro.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IMP:CAFA.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; NAS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; IMP:CAFA.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd08316; Death_FAS_TNFRSF6; 1.
DR   CDD; cd10579; TNFRSF6; 1.
DR   FunFam; 1.10.533.10:FF:000057; Tumor necrosis factor receptor superfamily member 6; 1.
DR   FunFam; 2.10.50.10:FF:000021; Tumor necrosis factor receptor superfamily member 6; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 2.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_dom.
DR   InterPro; IPR008063; Fas_rcpt.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   InterPro; IPR033998; TNFRSF6_death.
DR   InterPro; IPR033999; TNFRSF6_N.
DR   PANTHER; PTHR46874; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; 1.
DR   PANTHER; PTHR46874:SF1; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 2.
DR   PRINTS; PR01680; TNFACTORR6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 3.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF57586; TNF receptor-like; 2.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 2.
DR   PROSITE; PS50050; TNFR_NGFR_2; 2.
DR   neXtProt; NX_P25445; -.
DR   PharmGKB; PA36613; -.
DR   TreeFam; TF333916; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Calmodulin-binding;
KW   Cell membrane; Direct protein sequencing; Disease variant; Disulfide bond;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Proteomics identification; Receptor; Reference proteome; Repeat; Secreted;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..335
FT                   /note="Tumor necrosis factor receptor superfamily member 6"
FT                   /id="PRO_0000034563"
FT   TOPO_DOM        26..173
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        174..190
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..335
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          47..83
FT                   /note="TNFR-Cys 1"
FT   REPEAT          84..127
FT                   /note="TNFR-Cys 2"
FT   REPEAT          128..166
FT                   /note="TNFR-Cys 3"
FT   DOMAIN          230..314
FT                   /note="Death"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00064"
FT   REGION          212..317
FT                   /note="Interaction with HIPK3"
FT                   /evidence="ECO:0000250"
FT   REGION          230..254
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000269|PubMed:24914971"
FT   MOD_RES         209
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         214
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P25446"
FT   MOD_RES         225
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   LIPID           199
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:25301068"
FT   CARBOHYD        28
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:22171320"
FT   CARBOHYD        118
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        136
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        250
FT                   /note="(Microbial infection) N-beta-linked (GlcNAc)
FT                   arginine"
FT                   /evidence="ECO:0000269|PubMed:30979585,
FT                   ECO:0000305|PubMed:23955153"
FT   DISULFID        59..73
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        63..82
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        85..101
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        104..119
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        107..127
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        129..143
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        146..157
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   DISULFID        149..165
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00206"
FT   VAR_SEQ         66..103
FT                   /note="GERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRR -> DVNMESSRNA
FT                   HSPATPSAKRKDPDLTWGGFVFFFCQFH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7533181,
FT                   ECO:0000303|PubMed:7575433"
FT                   /id="VSP_006481"
FT   VAR_SEQ         66..86
FT                   /note="GERKARDCTVNGDEPDCVPCQ -> DVNMESSRNAHSPATPSAKRK (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7533181,
FT                   ECO:0000303|PubMed:7575433"
FT                   /id="VSP_006483"
FT   VAR_SEQ         87..335
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7533181,
FT                   ECO:0000303|PubMed:7575433"
FT                   /id="VSP_006484"
FT   VAR_SEQ         104..335
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7533181,
FT                   ECO:0000303|PubMed:7575433"
FT                   /id="VSP_006482"
FT   VAR_SEQ         112..149
FT                   /note="GLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKC -> DVNMESSRNA
FT                   HSPATPSAKRKDPDLTWGGFVFFFCQFH (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7575433,
FT                   ECO:0000303|PubMed:8648105"
FT                   /id="VSP_006485"
FT   VAR_SEQ         112..132
FT                   /note="GLEVEINCTRTQNTKCRCKPN -> DVNMESSRNAHSPATPSAKRK (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:8648105, ECO:0000303|Ref.8"
FT                   /id="VSP_006487"
FT   VAR_SEQ         133..335
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:8648105, ECO:0000303|Ref.8"
FT                   /id="VSP_006488"
FT   VAR_SEQ         150..335
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7575433,
FT                   ECO:0000303|PubMed:8648105"
FT                   /id="VSP_006486"
FT   VAR_SEQ         169..189
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:7533181,
FT                   ECO:0000303|PubMed:7575433"
FT                   /id="VSP_006489"
FT   VAR_SEQ         218..220
FT                   /note="ETV -> MLT (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:8598453"
FT                   /id="VSP_045235"
FT   VAR_SEQ         221..335
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:8598453"
FT                   /id="VSP_045236"
FT   VARIANT         16
FT                   /note="A -> T (in dbSNP:rs3218619)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_020008"
FT   VARIANT         25
FT                   /note="A -> T (in non-Hodgkin lymphoma; somatic mutation;
FT                   dbSNP:rs606231364)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013416"
FT   VARIANT         28
FT                   /note="T -> A (in ALPS1A; associated with autoimmune
FT                   hepatitis type 2)"
FT                   /evidence="ECO:0000269|PubMed:9322534"
FT                   /id="VAR_013417"
FT   VARIANT         82
FT                   /note="C -> R (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:9927496"
FT                   /id="VAR_013418"
FT   VARIANT         118
FT                   /note="N -> S (in squamous cell carcinoma; burn-scar
FT                   related; somatic mutation; dbSNP:rs121913083)"
FT                   /evidence="ECO:0000269|PubMed:10620127"
FT                   /id="VAR_018321"
FT   VARIANT         121
FT                   /note="R -> W (in ALPS1A; dbSNP:rs121913078)"
FT                   /evidence="ECO:0000269|PubMed:9028321"
FT                   /id="VAR_013419"
FT   VARIANT         122
FT                   /note="T -> I (in dbSNP:rs3218614)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_020009"
FT   VARIANT         178
FT                   /note="C -> R (in squamous cell carcinoma; burn-scar
FT                   related; somatic mutation; dbSNP:rs121913084)"
FT                   /evidence="ECO:0000269|PubMed:10620127"
FT                   /id="VAR_018322"
FT   VARIANT         180
FT                   /note="L -> F (in non-Hodgkin lymphoma; somatic mutation;
FT                   dbSNP:rs1848491059)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013420"
FT   VARIANT         183
FT                   /note="P -> L (in non-Hodgkin lymphoma; somatic mutation;
FT                   dbSNP:rs758835365)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013421"
FT   VARIANT         184
FT                   /note="I -> V (in dbSNP:rs28362322)"
FT                   /id="VAR_052347"
FT   VARIANT         198
FT                   /note="T -> I (in non-Hodgkin lymphoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013422"
FT   VARIANT         232
FT                   /note="Y -> C (in ALPS1A; no effect on interaction with
FT                   FADD; dbSNP:rs121913079)"
FT                   /evidence="ECO:0000269|PubMed:20935634,
FT                   ECO:0000269|PubMed:9028321"
FT                   /id="VAR_013423"
FT   VARIANT         241
FT                   /note="T -> K (in ALPS1A; dbSNP:rs201072885)"
FT                   /evidence="ECO:0000269|PubMed:10090885"
FT                   /id="VAR_013424"
FT   VARIANT         241
FT                   /note="T -> P (in ALPS1A; dbSNP:rs121913076)"
FT                   /evidence="ECO:0000269|PubMed:11418480,
FT                   ECO:0000269|PubMed:7540117"
FT                   /id="VAR_013425"
FT   VARIANT         249
FT                   /note="V -> L (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:10515860"
FT                   /id="VAR_065128"
FT   VARIANT         250
FT                   /note="R -> P (in ALPS1A; dbSNP:rs121913080)"
FT                   /evidence="ECO:0000269|PubMed:10515860,
FT                   ECO:0000269|PubMed:9927496"
FT                   /id="VAR_013426"
FT   VARIANT         250
FT                   /note="R -> Q (in ALPS1A; no effect on interaction with
FT                   FADD; dbSNP:rs121913080)"
FT                   /evidence="ECO:0000269|PubMed:10090885,
FT                   ECO:0000269|PubMed:20935634"
FT                   /id="VAR_013427"
FT   VARIANT         253
FT                   /note="G -> D (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:10515860"
FT                   /id="VAR_065129"
FT   VARIANT         253
FT                   /note="G -> S (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:10515860"
FT                   /id="VAR_065130"
FT   VARIANT         255
FT                   /note="N -> D (in squamous cell carcinoma; burn-scar
FT                   related; somatic mutation; dbSNP:rs121913082)"
FT                   /evidence="ECO:0000269|PubMed:10620127"
FT                   /id="VAR_018323"
FT   VARIANT         257
FT                   /note="A -> D (in ALPS1A; loss of interaction with FADD;
FT                   dbSNP:rs1848674892)"
FT                   /evidence="ECO:0000269|PubMed:20935634,
FT                   ECO:0000269|PubMed:9028957"
FT                   /id="VAR_013428"
FT   VARIANT         259
FT                   /note="I -> R (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:10515860"
FT                   /id="VAR_065131"
FT   VARIANT         260
FT                   /note="D -> G (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:9927496"
FT                   /id="VAR_013429"
FT   VARIANT         260
FT                   /note="D -> V (in ALPS1A; also found in non-Hodgkin
FT                   lymphoma; somatic mutation; loss of interaction with FADD;
FT                   dbSNP:rs28929498)"
FT                   /evidence="ECO:0000269|PubMed:11418480,
FT                   ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:9787134,
FT                   ECO:0000269|PubMed:9821419"
FT                   /id="VAR_013431"
FT   VARIANT         260
FT                   /note="D -> Y (in ALPS1A; loss of interaction with FADD;
FT                   dbSNP:rs121913086)"
FT                   /evidence="ECO:0000269|PubMed:20935634,
FT                   ECO:0000269|PubMed:8929361"
FT                   /id="VAR_013430"
FT   VARIANT         262
FT                   /note="I -> S (in ALPS1A)"
FT                   /evidence="ECO:0000269|PubMed:17336828"
FT                   /id="VAR_058910"
FT   VARIANT         264
FT                   /note="N -> K (in non-Hodgkin lymphoma; somatic mutation;
FT                   dbSNP:rs2119446116)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013432"
FT   VARIANT         270
FT                   /note="T -> I (in ALPS1A; dbSNP:rs121913081)"
FT                   /evidence="ECO:0000269|PubMed:11418480,
FT                   ECO:0000269|PubMed:9927496"
FT                   /id="VAR_013433"
FT   VARIANT         270
FT                   /note="T -> K (in ALPS1A; loss of interaction with FADD)"
FT                   /evidence="ECO:0000269|PubMed:10515860,
FT                   ECO:0000269|PubMed:20935634"
FT                   /id="VAR_065132"
FT   VARIANT         272
FT                   /note="E -> G (in ALPS1A; dbSNP:rs1589491089)"
FT                   /evidence="ECO:0000269|PubMed:10340403,
FT                   ECO:0000269|PubMed:11418480"
FT                   /id="VAR_013434"
FT   VARIANT         272
FT                   /note="E -> K (in ALPS1A; also found in non-Hodgkin
FT                   lymphoma; somatic mutation; loss of interaction with FADD)"
FT                   /evidence="ECO:0000269|PubMed:10515860,
FT                   ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013435"
FT   VARIANT         278
FT                   /note="L -> F (in non-Hodgkin lymphoma; somatic mutation;
FT                   dbSNP:rs2119446626)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013436"
FT   VARIANT         299
FT                   /note="K -> N (in non-Hodgkin lymphoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9787134"
FT                   /id="VAR_013437"
FT   VARIANT         305
FT                   /note="T -> I (in dbSNP:rs3218611)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_020942"
FT   VARIANT         310
FT                   /note="I -> S (in ALPS1A; dbSNP:rs2119448150)"
FT                   /evidence="ECO:0000269|PubMed:9028957"
FT                   /id="VAR_013438"
FT   MUTAGEN         199
FT                   /note="C->V: Loss of palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:25301068"
FT   MUTAGEN         250
FT                   /note="R->A: Abolished GlcNAcylation by E.coli NleB1."
FT                   /evidence="ECO:0000269|PubMed:30979585"
FT   MUTAGEN         250
FT                   /note="R->E: Strongly decreased interaction with FADD."
FT                   /evidence="ECO:0000269|PubMed:20935634"
FT   MUTAGEN         261
FT                   /note="E->K: Loss of interaction with FADD."
FT                   /evidence="ECO:0000269|PubMed:20935634"
FT   MUTAGEN         283
FT                   /note="Q->K: Loss of interaction with FADD."
FT                   /evidence="ECO:0000269|PubMed:20935634"
FT   MUTAGEN         287
FT                   /note="K->D: Strongly decreased interaction with FADD."
FT                   /evidence="ECO:0000269|PubMed:20935634"
FT   MUTAGEN         291
FT                   /note="Y->D: Decreased interaction with FADD."
FT                   /evidence="ECO:0000269|PubMed:19118384"
FT   MUTAGEN         313
FT                   /note="I->D: Constitutive activation. Promotes apoptosis,
FT                   both in the presence and in the absence of stimulation by a
FT                   ligand."
FT                   /evidence="ECO:0000269|PubMed:19118384"
FT   CONFLICT        224
FT                   /note="L -> F (in Ref. 11; AAR08906)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="L -> P (in Ref. 9; CAR92543)"
FT                   /evidence="ECO:0000305"
FT   STRAND          67..71
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   STRAND          75..77
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   TURN            87..89
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   STRAND          113..117
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   STRAND          126..129
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   STRAND          137..139
FT                   /evidence="ECO:0007829|PDB:3TJE"
FT   HELIX           174..181
FT                   /evidence="ECO:0007829|PDB:2NA7"
FT   HELIX           184..193
FT                   /evidence="ECO:0007829|PDB:2NA7"
FT   HELIX           232..242
FT                   /evidence="ECO:0007829|PDB:3EWT"
FT   TURN            251..253
FT                   /evidence="ECO:0007829|PDB:1DDF"
FT   HELIX           256..265
FT                   /evidence="ECO:0007829|PDB:3EZQ"
FT   HELIX           270..282
FT                   /evidence="ECO:0007829|PDB:3EZQ"
FT   HELIX           287..319
FT                   /evidence="ECO:0007829|PDB:3EZQ"
FT   HELIX           327..334
FT                   /evidence="ECO:0007829|PDB:3EZQ"
SQ   SEQUENCE   335 AA;  37732 MW;  0139942535111410 CRC64;
     MLGIWTLLPL VLTSVARLSS KSVNAQVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH
     KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT
     RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSNLGWLCLL
     LLPIPLIVWV KRKEVQKTCR KHRKENQGSH ESPTLNPETV AINLSDVDLS KYITTIAGVM
     TLSQVKGFVR KNGVNEAKID EIKNDNVQDT AEQKVQLLRN WHQLHGKKEA YDTLIKDLKK
     ANLCTLAEKI QTIILKDITS DSENSNFRNE IQSLV
//
